Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Cancer Therapies02:49

Cancer Therapies

9.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Cancer Survival Analysis01:21

Cancer Survival Analysis

601
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
601
Tumor Progression02:07

Tumor Progression

7.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.5K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immune Profiling Identifies Inflammatory Signatures in Immune Checkpoint Inhibitor-Related Myocarditis.

JACC. CardioOncology·2026
Same author

Model-based meta-analysis of individual patient data for the characterization of intravenous 5-fluorouracil population pharmacokinetics.

Cancer chemotherapy and pharmacology·2026
Same author

[Hepatopancreatobiliary surgery in 2026 : breakthroughs, challenges, and perspectives].

Revue medicale suisse·2026
Same author

Limb-sparing reconstruction using extracorporeal irradiation and autograft recycling for primary malignant bone tumors.

Clinical and translational radiation oncology·2026
Same author

Decision-Making in Intrathecal Therapy for Leptomeningeal Disease.

Oncology·2026
Same author

[Stereotactic radiotherapy of inoperable localized lung cancers].

Revue medicale suisse·2026

Related Experiment Video

Updated: Dec 30, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.5K

[Advances in Oncology 2019].

Anastasia Vernadou1, Nabila Ferahta1, Nuria Mederos1

  • 1Centre coordonné d'oncologie, CHUV, 1011 Lausanne.

Revue Medicale Suisse
|January 22, 2020
PubMed
Summary

2019 saw major oncology advances, with personalized treatments and biomarkers like PD-L1 and MSI improving patient care. Innovative therapies in development offer future hope for cancer treatment.

More Related Videos

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
08:26

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

2.5K
Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.4K

Related Experiment Videos

Last Updated: Dec 30, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.5K
Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
08:26

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

2.5K
Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.4K

Area of Science:

  • Oncology
  • Translational Medicine
  • Cancer Research

Background:

  • Oncology advanced significantly in 2019, driven by specialized medicine and personalized treatment research.
  • Existing cancer therapies gained broader applications and importance.
  • Emerging treatments showed promise for future breakthroughs.

Purpose of the Study:

  • To provide an overview of the key advances in oncology during 2019.
  • To highlight the role of biomarkers in personalizing cancer care.
  • To summarize progress in innovative cancer treatments.

Main Methods:

  • Review of 2019 oncology research and clinical developments.
  • Analysis of the impact of biomarkers on treatment selection.
  • Identification of emerging therapeutic strategies.

Main Results:

  • Numerous cancer treatments consolidated their roles and expanded indications.
  • Biomarkers such as PD-L1, MSI, TMB, BRCA1/2, and HRD facilitated personalized treatment selection.
  • Innovative therapies under investigation offered hope for future advancements.

Conclusions:

  • 2019 was a pivotal year for oncology, marked by treatment consolidation and personalization.
  • Biomarker-driven strategies are crucial for optimizing cancer therapy.
  • Ongoing research promises continued progress in combating cancer.